Drug Trial Radar · NCT07838220
A Study of IBI3016 in Japanese Participants
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Aug 1, 2026
Primary completion
Jan 30, 2027
Study completion Nov 5, 2027
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase I clinical study to evaluate the safety ,tolerability, pharmacokinetic and pharmocodynamic characteristics of a single subcutaneous does of IBI3016 in Japanese participants with mild to moderate hypertension.
Conditions
- Hypertension
Interventions
IBI3016 Dose 4Drug
single doses of IBI3016 administered by subcutaneous injection
IBI3016 Dose 3Drug
single doses of IBI3016 administered by subcutaneous injection
IBI3016 Dose 2Drug
single doses of IBI3016 administered by subcutaneous injection
IBI3016 Dose 1Drug
single doses of IBI3016 administered by subcutaneous injection
PlaceboDrug
single doses of IBI3016 administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse EventsTime frame: Through 24 weeks, up to approximately 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical Corporation Heishinkai OPHAC Hospital
Osaka, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.